A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Completed · Phase 2 · Has a placebo group

Conditions studied: Obesity

In brief

The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.

Key facts

Study ID

NCT06804603

Run by

Vanda Pharmaceuticals

People needed

124

Starts

2025-02-25

Expected to finish

2025-10-06

Last updated by the study team

2025-11-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body Mass Index 25-40 kg/m\^2 inclusive
• No serious medical problems or chronic diseases, specifically no type I or type II diabetes

You may not qualify if…

• Another disorder that contributes to gastrointestinal symptoms
• History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
• History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
• Exposure to any investigational medication within the past 60 days

Where it is running

• Vanda Investigational Site — Los Angeles, California, United States
• Vanda Investigational Site — Rochester, Minnesota, United States
• Vanda Investigational Site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.